Summary
Preclinical and clinical studies support the rationale that development of single molecules, which would promote serotonergic and noradrenergic neurotransmission by inhibiting simultaneously the uptake of both monoamines, would potentially result in improved antidepressant drugs. Currently, the dual inhibitors of serotonin and noradrenaline uptake are venlafaxine, milnacipran and duloxetine. Based on the preclinical studies, the three drugs do show properties of inhibiting uptake of both monoamines in vitro and in vivo in the following order of decreasing potency: duloxetine, venlafaxine and milnacipran, and all exhibit low affinity at neuronal receptors of neurotransmitters, suggesting low side-effect potential. In double-blind, controlled studies, venlafaxine and milnacipran were repeatedly shown to be as efficacious as tricyclic antidepressant drugs in treating major depressive disorder, while one double-blind, placebo-controlled trial showed the antidepressant efficacy of duloxetine. Specifically designed comparative trials of dual uptake inhibitors against the other agents are needed to establish whether the dual uptake inhibitors show improvement in efficacy, rate of responders, antidepressive effects and/or remission.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
C.L. Bowden, A.F. Schatzberg, A. Rosenbaum, S.A. Contreras, J.A. Samson, E. Dessain and M. Sayler: J. Clin. Psychopharmacol. 13, 305 (1993).
R.A. Remick, J. Claman, R. Reesal, R.E. Gibson, M.O. Agbayewa, R.W. Lam and F.D. Keller: Current Therapeutic Res. 53, 457 (1993).
P.E. Stokes: Clin. Therapeutics 15, 216 (1993).
D.C. Steffens, K.R. Krishnan and M.J. Helms: Depress. Anxiety 6, 10 (1997).
C.B. Nemeroff, in: J.M. Gorman and C.B. Nemeroff (chairs): The Role of Norepineph-rine in the Treatment of Depression (Academic Highlights). J Clin Psychiatry 60, 623 (1999).
C.M. Beasley, Jr, S.L. Holman and J.H. Potvin: Ann. Clin. Psychiatry 5, 199 (1993).
J.D. Armsterdam: J Psychopharmacol. 12, S99 (1998).
R.M.A. Hirschfield: J. Clin. Psychiatry 60: 326 (1999).
A.F. Schatzberg: J. Clin. Psychiatry 60 (Suppl. 4), 14 (1999).
M. Briley: Human Psychopharmacol. 13, 99 (1998).
J. Cookson: Brit. J. Psychiatry 163 (Suppl. 20), 20 (1993).
M.M. Katz, C. Bowden, P. Stokes, R. Casper, A. Frazer, S.H. Koslow, J. Kocsis, S. Secunda, A. Swann and N. Berman: Neuropsychopharmacol. 17, 110 (1997).
D. Hackett: Eur. Psychiatry 13, 117 (1998).
A.J. Gelenberg and C.L. Chesen: J. Clin. Psychiatry 61, 712 (2000).
A. Sambunaris, J.K. Hesselink, R. Pinder, J. Panagides and S.M. Stahl: J. Clin. Psychiatry 58 (Suppl. 6) 40 (1997).
D.T. Wong, D.W. Robertson, F.P. Bymaster, J.H. Krushinski and L.R. Reid: Life Sci. 43, 2049 (1988).
D.T. Wong: Exp. Opin. Invest. Drugs 7, 1 (1998).
P.L. Delgado, D.S. Charney, L.H. Price, G.K. Aghajanian, H. Landis and G.R. Heninger: Arch. Gen. Psychiatry 47, 411 (1990).
P.L. Delgado, H.L. Miller, R.M. Salomon, J. Licinio, J.H. Krystal, F.A. Moreno, G.R. Heninger and D.S. Charney: Biol. Psychiatry 46, 212 (1999).
P.L. Delgado and F.A. Moreno: J. Gin. Psychiatry 61 (Suppl. 1), 5 (2000).
D.T. Wong, J.S. Homg, F.P. Bymaster, K.L. Hauser and B.B. Molloy: Life Sci. 15, 471 (1974).
D.T. Wong, J.S. Horng and F.P. Bymaster: Life Sci. 17, 755 (1975).
R.W. Fuller and D.T. Wong: Fed. Proc. 36, 2154 (1977).
A. Coppen: Brit. J. Psychiatry 113, 1237 (1967).
H. Weil-Malherbe and S.I. Szara (eds): The biochemistry of functional and experimental psychosis. C.C. Thomas Publisher, Springfield, IL (1971), pp 57.
J.J. Schildkraut: Am. J. Psychiatry 122, 509 (1965).
W.E. Bunney, Jr. and J.M. Davis: Arch. Gen. Psychiatry 13, 483 (1965).
P.L. Delgado, H.L. Miller, R.M. Salomon, J. Licinio, G.R. Heninger, A.J. Gelenberg and D.S. Chamey: Psychopharmacol. Bull. 29, 389 (1993).
H.L. Miller, P.L. Delgado, R.M. Salomon, R. Berman, J.H. Krystal, G.R. Heninger and D.S. Charney: Arch. Gen. Psychiatry 53, 117 (1996).
W.Z. Potter, H.M. Calil, I. Extein, P.W. Gold, T.A. Wehr and F.K. Goodwin: Acta Psychi-atr. Scand. 290 (Suppl.), 152 (1981).
A. Aberg: Acta Psychiatr. Scand. 290 (Suppl.), 244 (1981).
J.B. Weilburg, J.F. Rosenbaum, J. Biederman, G.S. Sachs, M.H. Pollack, and K. Kelly: J. Clin. Psychiatry 50, 447 (1989).
J.C. Nelson, C.M. Mazure, M.B. Bowers Jr. and P.I. Jatlow: Arch. Gen. Psychiatry 48, 303 (1991).
R. Seth, A.L. Jennings, J. Bindman, J. Phillips and K. Bergmann: Brit. J. Psychiatry 161, 562 (1992).
J. Vetulani, R.J. Stawarz, J.V. Dingell and F. Sulser: Naunyn-Schmiedebergs Arch. Phar-macol. 293, 109 (1976).
R. Mishra, A. Janowsky and F. Sulser: Eur. J. Pharmacol. 60, 379 (1979).
D.T. Wong, L.R. Reid, F.P. Bymaster and P.G. Threlkeld: J. Neural. Transm. 64, 251 (1985).
N. Brunnello, M.L. Barbaccia, D.M. Chuang and E. Costa: Neuropharmacol. 21, 1145 (1982).
V.L. Nimgaonkar, G.M. Goodwin, C.L. Davies and A.R. Green: Neuropharmacol 24, 279 (1985).
C.A. Stockmeier, A.M. Matino and K.J. Kellar: Science 230, 323 (1985).
B.M. Baron, A.-M. Ogden, B.W. Siegel, J. Stegeman, R.C. Ursillo and M.W. Dudley: Eur. J. Pharmacol. 154, 125 (1988).
J.M. Baraban and G.K. Aghajanian: Neuropharmacol. 19, 355 (1980).
C.P. VanderMaelen and G.K. Aghajanian: Brain Res. 289, 109 (1983).
L.A. Dawson, H.Q. Nguyen and A. Geiger: Neuropharmacol. 38, 1153 (1999).
S. Hjorth, H.J. Bengtsson, S. Milano, J.F. Lundberg and T. Sharp: Neuropharmacol. 34, 615 (1995).
J.M. Baraban and G.K. Aghajanian: Eur. J. Pharmacol. 66, 287 (1980).
D.T. Wong, F.P. Bymaster, D.A. Mayle, L.R. Reid, J.H. Krushinski and D.W. Robertson: Neuropsychopharmacol. 8, 23 (1993).
C. Bolden-Watson and E. Richelson: Life Sci. 52, 1023 (1993).
C. Moret, M. Charveron, J.P.M. Finberg, J.P. Couzinier and M. Briley: Neuropharmacol. 24, 1211 (1985).
C. Sanchez and J. Hyttel: Cell. Mol. Neurobiol. 19, 467 (1999).
D.T. Wong, F.P. Bymaster, L.R. Reid, D.A. Mayle, J.H. Krushinski and D.W. Robertson: Neuropsychopharmacol. 8, 337 (1993).
E.H.F. Wong, M.S. Sonders, S.G. Amara, P.M. Tinholt, M.F.P. Piercey, W.P. Hoffmann, D.K. Hyslop, S. Franklin, R.D. Porsolt, A. Bonsignori et al.: Biol. Psychiatry 47, 818 (2000).
D.T. Wong, F.P. Bymaster and E.A. Engleman: Life Sci. 57, 411 (1995).
F.P. Bymaster, L.J. Dreshfield-Ahmad, P.G. Threlkeld, J.L. Shaw, L. Thompson, D.L.G. Nelson, S.K. Hemrick-Luecke and D.T. Wong: Neuropsychopharmacol. 25, 871–880 (2001).
M. Tatsumi, K. Groshan, R.D. Blakely and E. Richelson: Eur. J. Pharmacol. 340, 249 (1997).
D.T. Wong and F.P. Bymaster: Res. Comm. Chem. Pathol. Pharmacol. 15, 221(1976).
T. Kihara and M. Ikeda: J. Pharmacol. Exp. Ther. 272, 177 (1995).
D.T. Wong, F.P. Bymaster, L.R. Reid and P.G. Threlkeld: Biochem. Pharmacol. 32, 1287 (1983).
B. Cusack, A. Nelson and E. Richelson: Psychopharmacol. 114, 559 (1994).
A.I. Levey: Life Sci. 52, 441(1993).
T. Stanton, C. Bolden-Watson, B. Cusack and E. Richelson: Biochem. Pharmacol. 45, 2352 (1993).
E.-P., Palvimaki, B.L. Roth, H. Majasuo, A. Laakso, M. Kuoppamaki, E. Syvalahti and J. Hietala: Psychopharmacol. 126, 234, (1996).
C. Wikell, P.B.F. Bergqvist, S. Hjorth, G. Apelqvist, H. Bjork and F. Bengtsson: Clin. Neu-ropharmacol. 21, 296 (1998).
E. Carboni, G.L. Tanda, R. Frau and G. Di Chiara: J. Neurochem. 55, 1067 (1990).
C. Wikell, S. Hjorth, G. Apelqvist, J. Kullingsjo, J. Lundmark, P.B. Bergqvist and F. Bengts-son: Naunyn-Schmiedebergs Arch. Pharmacol. 363, 448 (2001).
S.E. Gartside, V. Umbers and T. Sharp: Psychopharmacol. 130, 261 (1997).
D.W. Gallager and G.K. Aghajanian: J. Pharmacol. Exp. Ther. 193, 785 (1975).
Y. Chaput, C. de Montigny and P. Blier: Naunyn-Schmiedebergs Arch. Pharmacol. 333, 342 (1986).
F. Artigas, L. Romero, C. de Montigny and P. Blier: Trends Neurosci. 19, 378, (1996).
L.J. Dreshfield, D.T. Wong, K.W. Perry and E.A. Engleman: Neurochem. Res. 21, 557(1996).
T. Sharp, V. Umbers and S. Hjorth: Neuropharmacol. 35, 735 (1996).
R. Tao and S. Hjorth: Naunyn Schmiedebergs Arch. Pharmacol. 345, 137 (1992).
E. Gur, E. Dremencov, B. Lerer and M.E. Newman: Eur. J. Pharmacol. 372, 17 (1999).
E.A. Muth, J.A. Moyer, J.T. Haskins, T.H. Andree and G.E.M. Husbands: Drug Dev. Res. 23, 191 (1991).
C. Moret and M. Briley: J. Neurochem. 69, 815, (1997).
N. Bel and F. Artigas: Neuropsychopharmacol. 21, 745 (1999).
N. Bel and F. Artigas: J. Pharmacol. Exp. Ther. 278, 1064 (1996).
S. Shuto, S. Ono, Y. Hase, Y. Ueno, T. Noguchi, K. Yoshii and A. Matsuda: J. Med. Chem. 39, 4844 (1996).
S. Shuto, H. Takada, D. Mochizuki, R. Tsujita, Y. Hase, S. Ono, N. Shibuya and A. Matsuda: J. Med. Chem. 38, 2964 (1995).
W. Loscher, R. Annies and D. Honack: Neurosci Lett. 128, 191 (1991).
J.M. Mathe, G.G. Nomikos, K.H. Blakemen and T.H. Svensson: Neuropharmacol. 38, 121(1999).
R. Trullas and P. Skolnick: Eur. J. Pharmacol. 185, 1 (1990).
P. Skolnick, B. Legutko, X. Li and F.P. Bymaster: Pharmacological Research 43, 411 (2001).
E.A. Engleman, K.W. Perry, D.A. Mayle and D.T. Wong: Neuropsychopharmacol. 12, 287 (1995).
M.J. Millan, M. Brocco, S. Veiga, L. Cistarelli, C. Melon and A. Gobert: Eur. J. Pharma-col. 341, 165 (1998).
E.A. Engleman, D.W. Robertson, D.C. Thompson, K.W. Perry and D.T. Wong: J. Neu-rochem. 66, 599 (1996).
A. Gobert, J.-M. Rivet, L. Cistarelli and M.J. Millan: J. Neurochem. 68, 1326 (1997).
G. Tanda, E. Carboni, R. Frau and G. Di Chiara: Psychopharmacol. 115, 285(1994).
A. Gobert, J-M Rivet, L. Cistarelli, C. Melon and M.J. Millan: J. Neurochem. 69, 2616 (1997).
J.J. Scuvee-Moreau and A.E. Dresse: Eur. J. Pharmacol. 57, 219 (1979).
M. Hajos, S.E. Gartside and T. Sharp: Naunyn-Schmiedebergs Arch. Pharmacol. 351, 624(1995).
P. Blier, C. de Montigny and D. Tardif: Psychopharmacol. 84, 242 (1984).
C. de Montigny, Y. Chaput and P. Slier: J. Clin. Psychiatry 51 (Suppl. B), 4 (1990).
K. Kasamo, P. Blier and C. de Montigny: J. Pharmacol. Exp. Ther. 277, 278 (1996).
J.C. Beique, C. de Montigny, P. Slier and G. Debonnel: Synapse 32, 198 (1999).
J.F. Czachura and K. Rasmussen: Naunyn-Schmiedebergs Arch. Pharmacol. 362, 266 (2000).
M.H. Sheard, A. Zolovick, and G.K. Aghajanian: Brain Res. 43, 690 (1972).
T.H. Svensson, B.S. Bunney and G.K. Aghajanian: Brain Res. 92, 291 (1975).
F. Lejeune, V. Audinot, A. Gobert, J.-M. Rivet, M. Spedding and M.J. Millan: Eur. J. Phar-macol. 260, 79 (1994).
N. Haddjeri, C. de Montigny and P. Blier: Brit. J. Pharmacol 120, 865 (1997).
N. Quinaux, J. Scuvee-Moreau and A. Dresse: Naunyn Schmiedebergs Arch. Pharmacol. 319, 66 (1982).
M. Salter, R. Hazelwood, C.I. Pogson, R. Iyer, D.J. Madge, H.T. Jones, B.R. Cooper, R.F. Cox, C.M. Wang and R.P. Wiard: Neuropharmacol. 34: 217 (1995).
R. Mongeau, M. Weiss, C. de Montigny and P. Slier: Neuropharmacol. 37, 905 (1998).
J.T. Haskins, J.A. Moyer, E.A. Muth and E.B. Sigg: Eur. J. Pharmacol. 115, 139 (1985).
J.P. Yardley, G.E.M. Husbands, G. Stack, J. Butch, J. Bicksler, J.A. Moyer, E.A. Muth, T. Andree, H. Fletcher 3rd, M.N. James et al.: J. Med. Chem. 33, 2899 (1990).
A. Katoh, M. Eigyo, C. Ishibashi, Y. Naitoh, M. Takeuchi, N. Ibii, M. Ikeda and A. Mat-sushita: J. Pharmacol. Exp. Ther. 272, 1067 (1995).
J.P. Redrobe, M. Bourin, M.C. Colombel and G.B. Baker: Psychopharmacol. 138,1 (1998).
A. Stenger, J.P. Couzinier and M. Briley: Psychopharmacol. 91, 147 (1987).
I.H. Slater, R.C. Rathbun and R. Kattau: J. Pharm. Pharmacol. 31, 108 (1979).
S. Schreiber, M.M. Backer and C.G. Pick: Neurosci. Lett. 273, 85 (1999).
S. Iyengar, D.L. Li, D.H. Lee, R.M.A. Simmons: World Biol. Psychiatry 2, 325S (2001).
E Subhan, P.N. Deslandes, D.M. Pache and R.D.E. Sewell: Eur. J. Pharmacol. 408, 257, (2000).
J. Maj and Z. Rogoz: J. Neural Transm. 106, 197 (1999).
E.A. Muth, J.T. Haskins, J.A. Moyer, G.E. Husbands, S.T. Nielsen and E.B. Sigg: Biochem. Pharmacol. 35, 4493 (1986).
J.-P. Reneric and I. Lucid: Psychopharmacol. 136, 190 (1998).
R.D. Porsolt, M. Le Pichon and M. Jalfre: Nature 266, 730 (1977).
T.J. Connor, P. Kelliher, Y. Shen, A. Harkin, J.P. Kelly and B.E. Leonard: Pharmacol. Biochem. Behay. 65, 591 (2000).
V. Molina, L. Ciesielski, S. Gobaille, F. Isel and P. Mandel: Pharmacol. Biochem. Behay. 27, 123 (1987).
P.J. Mitchell and A. Fletcher: Neuropharmacol. 32, 1001 (1993).
H.C. Jackson, A.M. Needham, L.J. Hutchins, S.E. Mazurkiewicz and D.J. Heal: Brit. J. Phar-macol. 121, 1758 (1997).
S.A. Montgomery: Intl. Clin. Psychopharmacol. 10 (Suppl. 2), 21 (1995).
R.C. Shelton: J. Clin. Psychiatry 60 (Suppl. 4), 57 (1999).
J.C. Nelson: J. Clin. Psychiatry 61 (Suppl. 2), 13 (2000).
P.L. Delgado, L.H. Price, H.L. Miller, R.M. Salomon, G.K. Aghajanian, G.R. Heninger and D.S. Charney: Arch. Gen. Psychiatry 51, 865 (1994).
J.C. Nelson: Biol. Psychiatry 46, 1301 (1999).
H.L. Goldberg and R. Finnerty: Psychopharmacol. Bull. 24, 198 (1988).
E. Schweizer, C. Clary, I. Fox and C. Weise and K. Rickels: Psychopharmacol. Bull. 24, 195 (1988).
E. Schweizer, C. Weise, C. Clary and K. Rickels: J. Clin. Psychopharmacol. 11, 233 (1991).
J.C. Costa e Silva: J. Clin. Psychiatry 59, 352 (1998).
G.E. Clerc, P Ruimy and J. Verdeau-Pailles: Int Clin Psychopharmacol. 9, 139 (1994).
J.H. Heiligenstein, G.D. Tollefson and D.E. Faries: Int. Clin. Psychopharmacol. 8, 247 (1993).
A.C. Pande and M.E. Sayler: Int. Clin. Psychopharmacol. 8, 243 (1993).
M. Thase, A.R. Entsuah and R.L. Rudolph: Brit. J. Psychiatry 178, 234 (2001).
J.D. Guelfi, C. White, D. Hackett, J.Y. Guichoux and G. Magni: J. Clin. Psychiatry 56, 450 (1995).
O. Benkert, G. Grunder, H. Wetzel and D. Hackett: J. Psychiatr. Res. 30, 441 (1996).
M.A. Scott, P.S. Shelton and W. Gattis: Pharmacotherapy 16, 352 (1996).
Wyeth-Ayerst: Venlafaxine (Effexor) package insert, Philadelphia, PA (1995).
J.D. Guelfi, M. Ansseau, E. Corruble, J.C. Samuelian, I. Tonelli, A. Toumoux and Y. Ple-tan: Int. Clin. Psychopharmacol. 13, 121 (1998).
J.P. Macher, J.P. Sichel, C. Serre, R. Von Frenckell, J.C. Huck and J.P. Demarez: Neuropsy-chobiology 22, 77(1989).
Y. Lecrubier, Y. Pletan, A. Solles, A. Tournoux and V. Magne: Int. Clin. Psychopharma-col. 11 (Suppl. 4), 29 (1996).
M. Ansseau, R. von Frenckell, C. Mertens, J. de Wilde, L. Botte, J.-M. Devoitille, J.-L. Evrard, A. De Nayer, P. Darimont, G. Dejaiffe et al.: Psychopharmacol. 98, 163 (1989).
A. Puech, S.A. Montgomery, J.F. Prost, A. Solles and M. Briley: Int. Clin. Psychopharma-col. 12, 99 (1997).
G. Clerc and the Milnacipran/Fluvoxamine Study Group: Int. Clin. Psychopharmacol. 16, 145 (2001).
J. Ishigooka, E. Nagata, A. Takahashi, T. Sugiyama, M. Uchiumi, T. Tsukahara, M. Murasaki, S. Mura, T. Oguma and Y. Yano: Curt Ther. Res. 58, 679 (1997).
M. Berk, A. du Plessis, M. Birkett and D. Richardt, on behalf of the Lilly Duloxetine study group: Int. Clin. Psychopharmacol. 12, 137 (1997).
A.F. Joubert, A.D. du Plessis, D. Faries and C.A. Gagiano: Biol. Psychiatry 42 (Suppl. 1), Abstr 86 (1997).
D.J. Goldstein, C. Mallinckrodt, Y. Lu and M.A. Demitrack: World J. Biol. Psychiatry 2 (suppl 1), 331S (2001).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2002 Springer Basel AG
About this chapter
Cite this chapter
Wong, D.T., Bymaster, F.P. (2002). Dual serotonin and noradrenaline uptake inhibitor class of antidepressants — Potential for greater efficacy or just hype?. In: Jucker, E. (eds) Progress in Drug Research. Progress in Drug Research, vol 58. Birkhäuser, Basel. https://doi.org/10.1007/978-3-0348-8183-8_5
Download citation
DOI: https://doi.org/10.1007/978-3-0348-8183-8_5
Publisher Name: Birkhäuser, Basel
Print ISBN: 978-3-0348-9468-5
Online ISBN: 978-3-0348-8183-8
eBook Packages: Springer Book Archive